Cargando…

Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemotherapy and stereotactic body radiotherapy followed by surgical resection

PURPOSE: The purpose of this study was to determine if somatic mutations are associated with clinical and pathologic outcomes in patients with borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) who were treated with neoadjuvant chemotherapy and stereotactic b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reddy, Abhinav V., Hill, Colin S., Sehgal, Shuchi, Ding, Ding, Hacker-Prietz, Amy, He, Jin, Zheng, Lei, Herman, Joseph M., Meyer, Jeffrey, Narang, Amol K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society for Radiation Oncology 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743453/ https://www.ncbi.nlm.nih.gov/pubmed/34986552 http://dx.doi.org/10.3857/roj.2021.00815

Ejemplares similares

The Timing of Surgery Following Stereotactic Body Radiation Therapy Impacts Local Control for Borderline Resectable or Locally Advanced Pancreatic Cancer
por: Lin, Timothy, et al.
Publicado: (2023)

Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity
por: Hill, Colin S., et al.
Publicado: (2022)

High local failure rates despite high margin‐negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi‐agent chemotherapy
por: Hill, Colin, et al.
Publicado: (2022)

Upfront Chemotherapy Followed by Stereotactic Body Radiation Therapy with or without Surgery in Older Patients with Localized Pancreatic Cancer: A Single Institution Experience and Review of the Literature
por: Reddy, Abhinav V., et al.
Publicado: (2022)

Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer
por: Rajagopalan, Malolan S, et al.
Publicado: (2013)

Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy
por: Reddy, Abhinav V., et al.
Publicado: (2021)

Optimizing neoadjuvant radiotherapy for resectable and borderline resectable pancreatic cancer using protons
por: Nichols, Romaine Charles, et al.
Publicado: (2019)

Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy
por: Reddy, Abhinav V., et al.
Publicado: (2022)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020)

Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
por: Massani, Marco, et al.
Publicado: (2023)

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy
por: Mikulic, Danko, et al.
Publicado: (2021)

Neoadjuvant chemotherapy and radiotherapy outcomes in borderline‐resectable and locally‐advanced pancreatic cancer patients
por: Botta, Gregory P., et al.
Publicado: (2022)

Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy
por: Cheng, Zhi, et al.
Publicado: (2018)

Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Janssen, Quisette P., et al.
Publicado: (2021)

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
por: Trinh, Katherine V., et al.
Publicado: (2020)

Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer
por: Holyoake, Daniel L.P., et al.
Publicado: (2016)

Inter-Breath-Hold Geometric and Dosimetric Variations in Organs at Risk during Pancreatic Stereotactic Body Radiotherapy: Implications for Adaptive Radiation Therapy
por: Hooshangnejad, Hamed, et al.
Publicado: (2023)

Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer
por: Shrestha, Bikram, et al.
Publicado: (2017)

MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor
por: Mitsuya, Koichi, et al.
Publicado: (2021)

Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer
por: Kim, Hyeong Seok, et al.
Publicado: (2017)

Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma
por: Iyengar, Siddharth, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
por: Alva-Ruiz, Roberto, et al.
Publicado: (2021)

Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
por: Versteijne, E., et al.
Publicado: (2018)

Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Cloyd, Jordan M., et al.
Publicado: (2020)

Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma
por: Jia, Angela Y., et al.
Publicado: (2019)

A safety study of intraoperative radiation therapy following stereotactic body radiation therapy and multi-agent chemotherapy in the treatment of localized pancreatic adenocarcinoma: study protocol of a phase I trial
por: Reddy, Abhinav V., et al.
Publicado: (2022)

Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives
por: Labori, Knut Jørgen
Publicado: (2022)

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
por: Fossaert, Violette, et al.
Publicado: (2022)

Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection of brain metastasis: a case series of 20 patients
por: Deguchi, Shoichi, et al.
Publicado: (2021)

What if: A retrospective reconstruction of resection cavity stereotactic radiosurgery to mimic neoadjuvant stereotactic radiosurgery
por: Acker, Gueliz, et al.
Publicado: (2023)

Dosimetric and motion analysis of margin-intensive therapy by stereotactic ablative radiotherapy for resectable pancreatic cancer
por: Heinzerling, John H, et al.
Publicado: (2011)

Survival outcome after stereotactic body radiotherapy for locally advanced and borderline resectable pancreatic cancer: A systematic review and meta-analysis
por: Liu, Shi, et al.
Publicado: (2021)

Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer
por: Oshima, Minoru, et al.
Publicado: (2020)

Prognostic value of neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials
por: Liu, Shangtong, et al.
Publicado: (2023)

Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
por: Katz, Matthew H G, et al.
Publicado: (2023)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
por: Hu, Qiancheng, et al.
Publicado: (2019)

MET-02 Neoadjuvant fractionated stereotactic radiotherapy followed by surgery for large brain metastasis with difficulty in en-block resection
por: Mitsuya, Koichi, et al.
Publicado: (2020)

Neoadjuvant FOLFIRINOX Application in Borderline Resectable Pancreatic Adenocarcinoma: A Retrospective Cohort Study
por: Paniccia, Alessandro, et al.
Publicado: (2014)

Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer
por: Yasuta, Sho, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3r96jrh46tjp1lck6242sfc7e7